Public Pharma for Europe Conference

Abundance co-director Keir Milburn recently represented Abundance at the Public Pharma for Europe conference in Brussels. He presented Abundance’s work developing a Public-Common Partnership approach to pharmaceutical production. The conference brought together a wide range of groups and individuals campaigning for public models of pharmaceutical research and production. It closed with a sense that a new movement was forming to break the monopoly of Big Pharma. It’s a vital task. Big Pharma's monopolies drain public money out of the NHS and won’t even produce the medicines we need. Our proposal for a PCP model for pharmaceutical production not only addresses these problems but by democratising investment decisions also allows us to open up a different, more holistic conception of health. In the next couple of months, we will be producing a report detailing our work on pharmaceutical production along with a proposition for the restructuring of the sector along democratic lines.

‍